The Centers for Medicare & Medicaid Services (CMS) announced Sept. 21 that it will reduce reimbursement rates for clinical laboratory services starting in 2027, aiming to align Medicare payments with private-sector rates and save taxpayers approximately $1 billion annually.
The agency confirmed that Medicare has been overpaying for lab services for years, with reimbursement rates for simple tests such as blood work and urinalysis running about 16% above the marketplace average. The updated fee schedule, finalized under the Consolidated Appropriations Act of 2026, reflects the most recent private insurer payment data collected under the Protecting Access to Medicare Act (PAMA).
CMS Administrator Dr. Mehmet Oz stated in a release that the changes will ensure Medicare does not pay more than private insurers for the same tests. "By releasing this preliminary information, we are providing greater transparency into the actual market rates for laboratory services, rooting out waste, and supporting better-informed pricing decisions across the healthcare system," Oz said.
The fee schedule for clinical lab services had not been updated since 2014 due to legislative delays, during which time commercial rates for these services declined substantially. CMS estimates the new rates will better reflect current market realities and reduce excessive spending.
Impact on Medicare Beneficiaries
The updated rates do not directly change out-of-pocket costs for most Medicare beneficiaries, as lab tests remain covered under Part B. However, the reimbursement adjustments could influence lab revenues and service availability, particularly in rural and underserved areas.
Industry Response
Laboratory industry groups criticized the cuts, warning they could threaten patient access to essential testing. Susan Van Meter, president of the American Clinical Laboratory Association, stated in a Sept. 22 release that the reductions "will impose steep annual payment cuts that threaten seniors’ access to essential laboratory services."
Dr. Jim Zhai, president of the College of American Pathologists, called the fee reductions unsustainable, stating that "cuts of this scale threaten the stability of the laboratory infrastructure that patients and physicians rely on for accurate and timely diagnoses."
CMS emphasized that the changes are intended to curb wasteful spending while maintaining access to necessary diagnostic services. The agency also noted that the updated rates apply to Medicaid and Affordable Care Act Exchanges, extending the impact beyond Medicare beneficiaries.